Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Chembiochem : a European Journal of Chemical Biology|October 4, 2002
Synthesis and structure-activity relationship of the isoindolinyl benzisoxazolpiperidines as potent, selective, and orally active human dopamine D4 receptor antagonistsJames A Hendrix, Stephen J Shimshock, Gregory M Shutske, et al.
Journal of Pharmacological and Toxicological Methods|November 22, 2024
Predicting clinical outcomes from off-target receptor interactions using Secondary Intelligence™Will S Redfern, Chris E Pollard, Mark Holbrook, et al.
Environmental Health Perspectives|September 24, 2021
Key Characteristics of Cardiovascular ToxicantsLars Lind, Jesus A Araujo, Aaron Barchowsky, et al.
Journal of Pharmacological and Toxicological Methods|June 21, 2025
Current practices on the measurement of electrocardiogram and hemodynamic parameters in non-rodent species in regulatory safety assessment studiesJean-Pierre Valentin, Todd Bourcier, Xuan Chi, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5Victor J Cee, Mike Frohn, Brian A Lanman, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a Potent, S1P3-Sparing Benzothiazole Agonist of Sphingosine-1-Phosphate Receptor 1 (S1P1)Brian A Lanman, Victor J Cee, Srinivasa R Cheruku, et al.
ACS Medicinal Chemistry Letters|February 21, 2015
An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular LiabilitiesYuan Cheng, James Brown, Ted C Judd, et al.
JCI Insight|March 26, 2020
Cardiovascular response to small-molecule APJ activationBrandon Ason, Yinhong Chen, Qi Guo, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Journal of Medicinal Chemistry|June 11, 2008
Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonistWilliam D Shipe, James C Barrow, Zhi-Qiang Yang, et al.
Pageof 7